DOCSLIB.ORG

Effects of Nitrous Oxide on Chloralhydrate Sedation of Young

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Effects of Nitrous Oxide on Chloralhydrate Sedation of Young SCIENTIFIC ARTICLES Effects Of Nitrous Oxide On Chloral Hydrate Sedation Of Young Children Milton 1. Houpt, D.D.S., Ph.D., R. Glenn Rosivack, D.D.S., Nathan Rozenfarb, Dr. Odont., Samuel R. Koenigsberg, D.M.D., M.S. Department of Pediatric Dentistry, University of Medicine & Dentistry of New Jersey, New Jersey Dental School Summary This study was performed to test the hypothesis that nitrous oxide augments the effects of chloral hydrate sedation of young children. Twenty children with a mean age of 32 months were sedated on two occasions with two different treatment regimens. All subjects received a standard dose of 50 mg/kg of chloral hydrate with or without nitrous oxide dunng each of two treatment visits. During one visit, the subjects received 50% nitrous oxide and 50% oxygen for a period of 20 minutes followed by 100% oxygen and, dunng the other visit, the reverse concentrations were used. All subjects were restrained in a Papoose Board* with an auxiliary head restraint. Successful sedation, as evident by lack of crying or movement which interrupted treatment, occurred in 84% of administrations. During the first twenty minutes, subjects receiving nitrous oxide moved and cried significantly less than when they were treated without nitrous oxide. During the remainder of the appointment, there was no difference in behavior between the two treatment regimens. Vital signs remained essentially unchanged throughout all treatment with the exception of transitory elevation of the pulse and respiratory rates, which usually occurred when the mouth prop was inserted and local anesthesia was administered. It is concluded that nitrous oxide augments the effect of chloral hydrate sedation of young children, but does not do so uniformly for all children receiving sedation. Sedation frequently is used when comprehensive the child be in good health, that two restorative den- treatment is performed for very young children. Orally tistry appointments were required, and that sedation administered chloral hydrate is used because of its was necessary in order to manage uncooperative wide margin of safety and relatively few adverse behavior as determined in a screening examination. effects."A However, there has been little research to substantiate the effect of nitrous oxide on chloral Medications hydrate sedation. All subjects received the manufacturer's recom- This study was conducted in order to test the mended standard dose of 50 mg/kg of chloral hydrate hypothesis that nitrous oxide would augment the ef- (Noctec®)** for both treatment visits. At the first ap- fects of chloral hydrate when used to sedate young pointment, the subjects were randomly assigned to children for dental treatment. receive either regimen A or B for the first appointment with the alternate regimen administered during the Method second appointment. Consequently, a crossover de- sign was used with each subject serving as its own Subjects control and the 20 subjects participated in 40 treat- Twenty children ranging in age from 23 to 46 ment sessions. Treatment regimen A consisted of months with a mean age of 31.8 months participated 50% nitrous oxide and 50% oxygen for the first 20 in the study. Requirements for participation were that minutes of treatment followed by 100% oxygen for the remainder of the appointment, which was usually 40-60 minutes. Treatment regimen B consisted of 1 00% oxygen forthe first 20 minutes followed by 50% Accepted for publication November 13, 1986. Address correspondence to Dr. Milton Houpt, Professor and Chairman, Department of Pediatric Dentistry, New Jersey Dental *Olympic Medical Group, Seattle, WA School, 100 Bergen Street, Newark, New Jersey 07103. **E.R. Squibb and Company, Princeton, N.J. 298 ANESTHESIA PROGRESS nitrous oxide and 50% oxygen. In addition, during the havioral rating was a summary of behavior exhibited treatment procedure, all children were restrained in a since the previous rating. Both the operator and the Papoose Board with auxiliary head restraint. Sub- independent observer were kept blind as to whether jects were without food or fluids for at least 8 hours. the patient received nitrous oxide or 100% oxygen, Following their arrival, the vital signs and behavior and a third individuat made all settings to the nitrous were evaluated. Chloral hydrate was then adminis- oxide machine, which was kept covered. A consen- tered and on 30 occasions the child was coaxed into sus rating was made by two investigators (M.H. and drinking the chloral hydrate solution. In the remaining S.K.) from videotapes of the procedures to verify the 10, the solution was administered orally with a reliability of the rating scales, which had been previ- syringe. The dosages of chloral hydrate ranged from ously established.5 565 mg to 955 mg with a mean of 867 mg. The child In the operatory, blood pressure, pulse and respi- then remained with the parent for 45 minutes during ration were recorded with the use of a Beckman which time the onset of sleep was checked every 5 R51 1-A polygraph unit. Pulse was measured from minutes. After 45 minutes the child was transferred to the subject's index finger, respiration was recorded the operatory for the start of treatment. from an abdominal pneumatic belt measuring movements of the diaphragm, and a transducer Evaluation mounted on the reservoir bag was used to monitor The degree of sleep, body movements, crying, exchange gases through the nose. A precordial blood pressure, pulse, respiration rate and pupil size stethescope was also used to monitor respiration. were evaluated before, during and after operative Figure 1 shows sample recordings of blood pressure, procedures. In the operatory, these variables were pulse, chest movements, and gas exchange through rated by an independent observer during mouth prop the nose. insertion, administration of local anesthesia, place- As a separate part of this study, there was an ment of rubber dam, and every 15 minutes thereafter attempt to corroborate the findings of Moore, et al.7 using separate rating scales (Tables 1-3). Each be- using airway obstruction to test the depth of sedation. The mandible was depressed for a maximum of 15 seconds to close the airway until the patient demon- TABLE 1 Rating Scale for Sleep strated some movement. This test was performed on two occasions during the first and second parts of Score treatment, except when the patient was obviously Fully awake, alert 1 awake. It was performed after the 60 minute be- Drowsy, disoriented 2 havioral ratings and before the gas change, and it Asleep 3 was performed after the 75 minute rating which was after the gas change. TABLE 2 Rating Scale for Movement Score ........ ., Violent movement that ...........,i .;, .; (,:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~... ... interrupts treatment 1 Continuous movement that makes treatment difficult 2 Controllable movement that does not interfere with treatment 3 No movement 4 TABLE 3 Rating Scale for Crying Score Hysterical crying that interrupts treatment 1 Continuous, persistent crying that makes treat- ment difficult 2 Fig. 1 - Sample recordings of vital signs. Top channel records blood pressure intermittently, and the next channel dis- Intermittent, mild crying plays pulse continuously. (Note that the pulse record that does not interfere disappears as the blood pressure cuff is inflated, reduc- with treatment 3 ing the blood flow through the finger monitor.) The next No crying 4 two channels indicate respiration as monitored by gas exchange through the nose and by chest movements. NOVEMBER/DECEMBER 1986 299 Data Analysis No This experiment was designed so that each sub- Movement 4 ject could serve as its own control with the same time ..*~~~~~.06 of day, the same operator and similar types of proce- SlIght 3 dures during both treatment sessions. The indepen- Gas dent variable was the use of nitrous oxide and the Contnuous 2 - Chang dependent variable was the effectiveness of chloral hydrate sedation as measured the of by degree cry- Vbbnt 1 I With Nitrous Oxide ing and movement which interfered with treatment. - Wihout Nitrous Oxide Since the rating scales used the ordinal scale of measurement with related samples, the nonparamet- Mth Injeion 60 Mi 75 Min. 90 Min. ric sign rank test was used to compare the groups for PMp statistically significant differences. Fig. 2 - Evaluation of movement. Mean ratings are shown for subjects receiving nitrous oxide compared with subjects not receiving nitrous oxide at each of five periods of Results observation. Note that subjects receiving regimen A are represented by the solid line before the gas change and Rater Reliability by the broken line after the gas change. When the ratings made in the operatory were com- pared with the ratings made from videotapes, 300 Evaluation of Crying ratings were identical, 83 differed by one scale point Figure 3 shows the means of ratings of crying for all and 11 differed by two scale points producing 76% subjects at the various times of evaluation. For sub- agreement between the sets of ratings. jects receiving nitrous oxide the mean ratings at the five periods of observation were 3.15, 3.05, 2.95, Evaluation of Sleep 3.50, and 3.75, and the range of ratings at all periods Of the 40 treatment sessions, on 16 occasions was 1 to 4. For subjects receiving only oxygen, the patients fell asleep in the waiting area after an aver- mean ratings were 2.90, 2.25, 2.95, 3.40 and 3.40, age of 20 minutes; in the remaining 24 treatment and the range similarly was 1 to 4. Most subjects sessions, patients were awake when brought into the exhibited either no crying or occasional mild intermit- operatory. In 43% of the occasions that sleep was tent crying that did not interfere with the procedures. evaluated during treatment, all subjects were alseep. However, in 30% of the time, continuous persistent However, in 24% of the time, subjects were drowsy crying was exhibited.
Load more

Recommended publications
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Toxicological Review of Chloral Hydrate (CAS No. 302-17-0) (PDF)
    EPA/635/R-00/006 TOXICOLOGICAL REVIEW OF CHLORAL HYDRATE (CAS No. 302-17-0) In Support of Summary Information on the Integrated Risk Information System (IRIS) August 2000 U.S. Environmental Protection Agency Washington, DC DISCLAIMER This document has been reviewed in accordance with U.S. Environmental Protection Agency policy and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at http://www.epa.gov/iris. ii CONTENTS—TOXICOLOGICAL REVIEW for CHLORAL HYDRATE (CAS No. 302-17-0) FOREWORD .................................................................v AUTHORS, CONTRIBUTORS, AND REVIEWERS ................................ vi 1. INTRODUCTION ..........................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS ..... 2 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ............................3 4. HAZARD IDENTIFICATION ................................................6 4.1. STUDIES IN HUMANS - EPIDEMIOLOGY AND CASE REPORTS .................................................6 4.2. PRECHRONIC AND CHRONIC STUDIES AND CANCER BIOASSAYS IN ANIMALS ................................8 4.2.1. Oral ..........................................................8 4.2.2. Inhalation .....................................................12 4.3. REPRODUCTIVE/DEVELOPMENTAL STUDIES ..........................13
    [Show full text]
  • Chloral Hydrate and Paraldehyde As Drugs of Addiction
    Sept., 1932J CHLORAL HYDRATE DRUG HABIT : CHOPRA & SINGH CHOPRA 481 certain parts of the Punjab. This is not the outcome of the use of the drug in the treatment Original Articles of insomnia, but is due to entirely different causes. Until a few years ago in that province potable country-made spirits were allowed to CHLORAL HYDRATE AND PARALDE' be sold to retail dealers in bulk and the vendors HYDE AS DRUGS OF ADDICTION bottled the liquor themselves. Some of these ingenious people conceived the idea of diluting R. N. m.d. By CHOPRA, m.a., (Cantab.) the spirit and adding small quantities of chloral I.M.S. LIEUTENANT-COLONEL, hydrate to make up for the loss in its potency and which would result from dilution. The know- GURBAKHSH SINGH CHOPRA, m.b., b.s. ledge that the drug had hypnotic and narcotic was obtained from the (Drug Addiction Inquiry, Indian Research Fund effects undoubtedly Association) medical profession and compounders work- in It was further learnt that Series No. 15 ing dispensaries. the effects chloral hydrate in many Chloral produced by hydrate and paraldehyde belong to resemble those by alcohol, the of ways produced group drugs known as soporifics or especially when the latter is taken in large The chief use of hypnotics. this class of drugs quantities. When the two articles are taken is in the treatment of one insomnia, of the together they act in a manner synergistic to worst evils of modern times from which man- each other and in this way the effect of either kind can suffer.
    [Show full text]
  • Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Common Mechanism S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/21/mol.117.108290.DC1 1521-0111/91/6/620–629$25.00 https://doi.org/10.1124/mol.117.108290 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:620–629, June 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely through a Common Mechanism s Anita Luethy, James D. Boghosian, Rithu Srikantha, and Joseph F. Cotten Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (A.L., J.D.B., and J.F.C.); Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.); Carver College of Medicine, University of Iowa, Iowa City, Iowa (R.S.) Received January 7, 2017; accepted March 20, 2017 Downloaded from ABSTRACT The TWIK-related acid-sensitive potassium channel 3 (TASK-3; hydrate (165% [161–176]) . 2,2-dichloro- . 2-chloro 2,2,2- KCNK9) tandem pore potassium channel function is activated by trifluoroethanol . ethanol. Similarly, carbon tetrabromide (296% halogenated anesthetics through binding at a putative anesthetic- [245–346]), carbon tetrachloride (180% [163–196]), and 1,1,1,3,3,3- binding cavity. To understand the pharmacologic requirements for hexafluoropropanol (200% [194–206]) activate TASK-3, whereas molpharm.aspetjournals.org TASK-3 activation, we studied the concentration–response of the larger carbon tetraiodide and a-chloralose inhibit. Clinical TASK-3 to several anesthetics (isoflurane, desflurane, sevoflurane, agents activate TASK-3 with the following rank order efficacy: halothane, a-chloralose, 2,2,2-trichloroethanol [TCE], and chloral halothane (207% [202–212]) .
    [Show full text]
  • Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial
    85 Emergency (2014); 2 (2): 85‐89 ORIGINAL RESEARCH Oral Chloral Hydrate Compare with Rectal Thiopental in Pediatric Procedural Sedation and Analgesia; a Randomized Clinical Trial Reza Azizkhani1, Soheila Kanani1*, Ali Sharifi2, Keihan Golshani1, Babak Masoumi1, Omid Ahmadi1 1. Department of Emergency Medicine, Isfahan University of Medical Sciences, Isfahan, Iran 2. Department of General Surgery, Isfahan University of Medical Sciences, Isfahan, Iran Abstract Introduction: The increasing use of diagnostic imaging in pediatric medicine has resulted in growing need for procedural sedation and analgesia (PSA) to minimize motion artifacts during procedures. The drug of choice in pediatric PSA was not introduced till now. The aim of the present study was comparison of oral chloral hydrate (OCH) and rectal sodium thiopental (RST) in pediatric PSA. Methods: In the present randomized clinical trial, 2‐6 years old pediatrics who referred for performing brain computed tomography scan was enrolled and were randomly divided in to two groups. OCH (50mg/kg) and RST (25mg/kg) were prescribed and a trained nurse recorded the time from drug prescription to receiving the con‐ scious sedation (onset of action), the total time period which the patient has the Ramsay score≥4 (duration of action), and adverse effect of agents. Mann‐Whitney U test and chi‐squared test, and Non‐parametric analysis of covariance (ANCOVA) were used for comparisons. Results: One hundred and forty children were entered to two groups of OCH and RST, randomly. The patients of two groups had similar age, sex, weight, and baseline vital signs except for diastolic blood pressure (p<0.001). The onset of action in OCH and RST groups were 24.5±6.1and 28.7±5.2 minutes, respectively (p<0.001).
    [Show full text]
  • HS 172 R5/13 Briefly Review the Objectives, Content and Activities of This Session
    HS 172 R5/13 Briefly review the objectives, content and activities of this session. Upon successfully completing this session the participant will be able to: • Explain a brief history of the CNS Depressant category of drugs. • Identify common drug names and terms associated with this category. • Identify common methods of administration for this category. • Describe the symptoms, observable signs and other effects associated with this category. CONTENT SEGMENTS LEARNING ACTIVITIES A. Overview of the Category Instructor-Led Presentations B. Possible Effects Instructor Led Demonstrations C. OtdDtifEfftOnset and Duration of Effects RdiAiReading Assignmen ts D. Overdose Signs and Symptoms Video Presentations E. Expected Results of the Evaluation Slide Presentations F. Classification Exemplar HS 172 R5/13 9-2 • Explain the typical time parameters, i.e. onset and duration of effects, associated with this category. • List the clues that are likely to emerge when the drug influence evaluation is conducted for a person under the influence of this category of drugs. • Correctly answer the “topics for study” questions at the end of this session. HS 172 R5/13 9-3 A. Overview of the Category CNS Depressants Central Nervous System Depressants slow down the operations of the brain. Point out that other common names for CNS Depressants are “downers” and “sedative-hypnotics.” • Depressants first affect those arareaseas of the brain that control a person’ s conscious, voluntary actions. • Judgment, inhibitions and reaction time are some of the things that CNS Depressants affect first. • As the dose is increased, depressants begin to affect the parts of the brain that control the body’s automatic processes, heartbeat, respiration, etc.
    [Show full text]
  • Chloral Hydrate Safety Issues
    December 2016 www.nursingcenter.com Chloral Hydrate Safety Issues Chloral hydrate is a sedative-hypnotic that has been associated with serious adverse events in the pediatric population including dosing errors, over-sedation, and administration of the oral liquid by the intravenous (IV) route. In 2012, commercially available chloral hydrate products were discontinued and taken off the market. However, some ambulatory and hospital pharmacies are compounding an oral suspension of chloral hydrate for pediatric sedation in both inpatient and outpatient settings. Section 503A of the Federal Food, Drug and Cosmetic Act permits pharmacists to compound chloral hydrate to provide patient specific prescriptions in limited quantities. Compounded drugs are not approved by the US Food and Drug Administration (FDA), which means the FDA does not verify the safety or effectiveness of compounded drugs. One study found that compared to the commercial formulation, the compounded drug provided a shorter duration of sedation, more frequent need for an additional sedation agent, and frequent sedation failure. Over the last two years, there have been three reported cases of pediatric chloral hydrate overdoses and one death that occurred in the outpatient setting. Respiratory depression and arrest are two serious adverse events that can occur following chloral hydrate administration. Other risks associated with chloral hydrate use include: Resedation after discharge. Chloral hydrate can result in prolonged sedation or resedation with effects lasting longer than 24 hours in children of all ages, even if they appear to have cleared the sedation prior to discharge. Chloral hydrate is converted to trichloroethanol, which has a half-life of up to 66 hours in neonates, 28-40 hours in infants, 8-12 hours in children, and longer following an overdose.
    [Show full text]
  • Chloral Hydrate
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 December 2002 NTP TR 503 NIH Publication No. 03-4437 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NCTR and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Slipping a Mickey? Facts Around Drugs, Alcohol and Sexual Assault
    Slipping a Mickey? Facts around drugs, alcohol and sexual assault DR CATHY STEPHENSON OCTOBER 2011 Slipping a Mickey? Phrase coined in late 19th century Chicago barman Mickey Finn used “knock-out” drops to incapacitate and rob his patrons Probably used chloral hydrate Centuries old practise – other drugs in historical literature include alcohol, barbiturates and scopolamine Recently much media coverage of “date rape” drugs and “drink-spiking” Case 1 18 yo girl, seen 7 hours post sexual assault Party, 5 RTDs in 2.5 hours – left one open on the table Shortly after felt “strange” Taken home by friend’s father In car, forced oral and vaginal penetration Diazepam found on hair samples, but not urine Case 2 16 year old girl Seen 6 months after SA Risk-taking behaviour prompted disclosure ETOH + marijuana + antidepressant Much more common scenario Case 3 23 year old girl Seen 20 hours after sexual assault In town with friends Drinking Offered a ride home Raped in car outside her flat DFSA? Victims subjected to non-consensual sexual activity while they are incapacitated or unconscious through the effect of alcohol or drugs (1) Thereby prevented from resisting and unable to give consent Ingestion can be voluntary, involuntary or both DFSA may be “proactive” or “opportunistic”(2) So how often does it really happen? No reliable data in literature Reporting of SA in general very low 21% of females and almost 5% of males in Australia report a lifetime history of sexual coercion(3) Analysis of 1200 urine samples from sexual
    [Show full text]
  • Sedation in Fmri : an Unsolved Challenge
    Sedation in fMRI : An unsolved challenge Byron Bernal *, MD Nolan Altman**, MD There are many medications that can be utilized to sedate children undergoing fMR examinations. The most frequently used drugs are chloral hydrate, thiopenthal, phenobarbital, propofol, and fentanyl. These medications have some secondary effects on the electrical and metabolic activity of the cortex, cerebral blood flow(CBF), cerebral blood volume(CBV), and tissue oxygen extraction. These effects are of no concern in regular MRI (Magnetic Resonance Imaging), however, may have a significant contribution in fMR performed in the sedated child. Since fMRI is based on the hemodynamic and metabolic response of the brain to a given stimulus the selection of the sedation medication seems crucial. The following reviews the current knowledge regarding the relation of these drugs to these physiological parameters. Chloral Hydrate.- Chloral hydrate (CH) does not reduce brain cortex activity. This is demonstrated on EEG where it is widely used. Thoresen M and Henriksen O (1997) did not find changes on the EEGs in 9 out of 13 children with epileptic seizures, before and after CH was administered. We do not know of any reported studies relating CBF, CBV, or cerebral regional metabolism changes, and CH in humans. Propofol.- Propofol has been used as a sedative in children undergoing EEGs. Low propofol doses (0.5- 1 mg/kg) show an increase in the number of beta-waves and a significant reduction of alpha- and theta- waves . Larger doses of propofol (total dose of 2-2.5 mg/kg), the number of beta-waves decreased and delta-waves appeared.
    [Show full text]
  • Isoflurane, 2-Halogenated Ethanols, and Halogenated Methanes Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Similar Mechanism
    Isoflurane, 2-Halogenated Ethanols, and Halogenated Methanes Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Similar Mechanism. Authors: Joseph F. Cotten, M.D.,Ph.D1., Anita Luethy, M.D.1,2 1Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA. 2Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland. Background: TASK-3 (KCNK9) tandem pore potassium channel proteins mediate a constitutive potassium conductance activated by several clinically relevant volatile anesthetics (e.g., halothane, isoflurane, sevoflurane, and desflurane); knockout mice lacking the TASK-3 potassium channel are resistant to the hypnotic and immoblizing effects of halothane and isoflurane. Purpose: To better understand the molecular mechanism by which TASK-3 channels are activated by anesthetics, we studied the functional concentration-response of wild-type TASK-3 potassium channels to isoflurane, to ethanol, and to several halogenated ethanols and methanes. We also studied the concentration-response of M159W TASK-3 to 2,2,2- trichloroethanol; the M159W TASK-3 mutant is known to be resistant to isoflurane activation (1). 2,2,2-trichloroethanol, notably, is an active metabolite of the sedative chloral hydrate; and 2,2,2-tribromoethanol is the active ingredient in Avertin, an injectable veterinary anesthetic. Methods: Wild-type and M159W TASK-3 function were studied by Ussing chamber voltage clamp analysis during transient expression in Fischer rat thyroid cell monolayers. Results: 2-halogenated ethanols activate wild-type TASK-3 with the following rank order for efficacy: 2,2,2-tribromo > 2,2,2-trichloro > chloral hydrate > 2,2-dichloro > 2-chloro ≈ 2,2,2- trifluoro > ethanol (Table 1).
    [Show full text]
  • Chloral Hydrate: Summary Report
    Chloral Hydrate: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Chloral Hydrate Rights Attribution-NoDerivatives 4.0 International Download date 26/09/2021 09:06:16 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12087 Summary Report Chloral Hydrate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]